Literature DB >> 21524048

Medical management of stable coronary artery disease.

Matthew Pflieger1, Bradford T Winslow, Kyle Mills, Ira M Dauber.   

Abstract

All patients with stable coronary artery disease require medical therapy to prevent disease progression and recurrent cardiovascular events. Three classes of medication are essential to therapy: lipid-lowering, antihypertensive, and antiplatelet agents. Lipid-lowering therapy is necessary to decrease low-density lipoprotein cholesterol to a target level of less than 100 mg per dL, and physicians should consider a goal of less than 70 mg per dL for very high-risk patients. Statins have demonstrated clear benefits in morbidity and mortality in the secondary prevention of coronary artery disease; other medications that can be used in addition to statins to lower cholesterol include ezetimibe, fibrates, and nicotinic acid. Blood pressure therapy for patients with coronary artery disease should start with beta blockers and angiotensin-converting enzyme inhibitors. If these medications are not tolerated, calcium channel blockers or angiotensin receptor blockers are acceptable alternatives. Aspirin is the first-line antiplatelet agent except in patients who have recently had a myocardial infarction or undergone stent placement, in which case clopidogrel is recommended. Anginal symptoms of coronary artery disease can be treated with beta blockers, calcium channel blockers, nitrates, or any combination of these. Familiarity with these medications and with the evidence supporting their use is essential to reducing morbidity and mortality in patients with coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21524048

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  5 in total

1.  Quality of Cardiovascular Disease Care in Small Urban Practices.

Authors:  Donna Shelley; Batel Blechter; Nina Siman; Nan Jiang; Charles Cleland; Gbenga Ogedegbe; Stephen Williams; Winfred Wu; Erin Rogers; Carolyn Berry
Journal:  Ann Fam Med       Date:  2018-04       Impact factor: 5.166

2.  Innovative Practice, Clinical Research, and the Ethical Advancement of Medicine.

Authors:  Jake Earl
Journal:  Am J Bioeth       Date:  2019-06       Impact factor: 11.229

3.  Management and clinical outcome of stable coronary artery disease in Austria : Results from 5 years of the CLARIFY registry.

Authors:  Irene M Lang; Roza Badr-Eslam; Nicola Greenlaw; Robin Young; Philippe Gabriel Steg
Journal:  Wien Klin Wochenschr       Date:  2017-09-14       Impact factor: 1.704

4.  An investigation of changes in regional gray matter volume in cardiovascular disease patients, pre and post cardiovascular rehabilitation.

Authors:  U C Anazodo; J K Shoemaker; N Suskin; K S St Lawrence
Journal:  Neuroimage Clin       Date:  2013-10-06       Impact factor: 4.881

5.  Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice.

Authors:  Kyung-Yeon Park; Euichaul Oh; Mi-Kyoung Kwak; Hyun Sik Jun; Tae-Hwe Heo
Journal:  PLoS One       Date:  2016-03-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.